Wednesday, May 13, 2015 11:47:45 PM
http://www.marketwatch.com/story/corcept-therapeutics-mifepristone-combined-with-eribulin-to-improve-antitumor-activity-in-patients-with-triple-negative-breast-cancer-2015-05-13
Patients with metastatic breast cancer (five with triple-negative breast cancer) were treated with mifepristone and eribulin at three different dose levels. The study consisted of seven patients with GR-positive tumors, three patients with GR-negative tumors and three patients with unknown GR status. Two partial responses have been observed, both in patients with GR-positive cancer.
The study title shows it includes patients who do not have triple negative breast cancer:
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT02014337?term=Triple+Negative+Breast+Cancer+mifepristone&rank=1
In fact, the study accepts Breast Cancer, Ovarian Epithelial Cancer Recurrent, Sarcoma, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Prostate Cancer, Prostatic Neoplasms
From the title of the press release, one would assume that of the two partial responses, at least one of them was in TNBC, but it's not entirely clear from the text.
What's clear is that both patients had GR-positive tumors and advanced disease.
From the press release: An additional 20 patients with GR-positive metastatic TNBC will be enrolled into the study’s efficacy phase.
Recent CORT News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/09/2024 04:35:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 12:23:02 AM
- Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/01/2024 08:05:00 PM
- Corcept Completes Enrollment in Phase 4 CATALYST Trial • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call • GlobeNewswire Inc. • 04/24/2024 08:05:00 PM
- Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome • GlobeNewswire Inc. • 04/22/2024 12:00:00 PM
- Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome • GlobeNewswire Inc. • 04/01/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 02:19:45 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 02:14:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 02:09:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 02:03:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 02:02:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:41:18 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 10:24:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:11:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 01:06:33 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/16/2024 05:12:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/15/2024 09:17:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:11:41 PM
- Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/15/2024 09:07:00 PM
- Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial • GlobeNewswire Inc. • 02/15/2024 09:02:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/15/2024 08:45:41 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:23:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM